The degenerative condition sees the protective cartilage in the joint wear down, causing pain, stiffness and swelling.
Alpelisib plus fulvestrant significantly improved PFS in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, achieving a median PFS of 7.4 months versus 2.8 months with placebo. The ...
Most Democratic-led states will continue to recommend the hepatitis B vaccine at birth, despite a CDC advisory panel’s vote ...
The Food and Drug Administration has launched a safety review of two approved RSV drugs for infants, the latest immunizations ...
ProtonDx and Exhalon will each receive $1 million in seed funding to evaluate proof-of-concept rapid diagnostic tests based ...
A representative from Sanofi told Reuters that the safety of Beyfortus has been repeatedly shown in over 50 studies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback